VEEVA-SYSTEMS
Veeva Systems (NYSE: VEEV) today announced that TFS HealthScience selected Veeva Vault Clinical Operations Suite for end-to-end study management on a single cloud platform. The global CRO is taking action to further modernize study operations, adopting the entire suite for greater efficiency and speed in trials. Now TFS HealthScience will offer its biopharma customers industry-leading technologies and services to run more cost-efficient and compliant studies.
"Veeva Vault Clinical Operations Suite gives us a foundation for further growth as we expand our service offerings globally," said Dr. Bassem Saleh, CEO, TFS HealthScience. "Bringing together study operations streamlines processes, enabling us to maximize value for sponsors and accelerate the delivery of treatments to patients."
TFS HealthScience provides customers with strategically tailored solutions focused on driving excellence and innovation to reduce complexity in trials. Building on its success with Veeva Vault eTMF to maintain inspection readiness, the company will use Veeva Vault Study Startup to get studies up and running quickly, Veeva Vault CTMS to keep studies on track, and Veeva Vault Payments to simplify payments to global partner sites. With a connected, agile clinical landscape, TFS HealthScience will centralize governance and study oversight to share insights with sponsors easily.
"With Veeva Vault, we now have complete visibility into study progress and deviations to make better, more informed decisions and ensure studies meet their objectives," said Young Shon, CIO, TFS HealthScience. "Our partnership with Veeva is instrumental to TFS's digital transformation program and our strategic push towards paperless and patient-centric approaches."
"TFS HealthScience is transforming clinical operations to work more efficiently and better serve sponsors," said Pinar Benet, senior director strategy, Vault Clinical Operations at Veeva Systems. "We're excited to continue this journey together towards unified and connected trials to accelerate clinical research."
Vault Clinical Operations Suite enables sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, study start-up, and payments for better collaboration and increased efficiency throughout the study lifecycle.
The Veeva Unified Clinical Operations Survey: Annual CRO Report shows that CROs like TFS HealthScience are moving to streamline trial execution by embracing new digital strategies and technologies that eliminate data silos and manual processes. Learn how CROs are modernizing clinical operations to speed trials in the full report, available online at veeva.com/CROReport .
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About TFS HealthScience
TFS HealthScience is a global contract research organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working for a healthier future. Bringing together nearly 700 professionals, TFS delivers tailored clinical research services in more than 40 countries and supports customers with comprehensive solutions through three strong business models: clinical development services (CDS), which provides full-service support at all stages of the clinical development process, strategic resourcing solutions (SRS), which offers expert insourcing and targeted recruitment services, and functional services (FSP), to provide customers with strategic workforce management solutions. For more information, visit www.tfscro.com
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2020. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005312/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Buro Happold Signs Landmark Agreement with Expo 2030 Riyadh Company to Deliver Detailed Master Plan and Infrastructure and Public Realm Design for Expo 2030 Riyadh2.12.2025 11:00:00 CET | Press release
Buro Happold, a leading global engineering, design and advisory consultancy, has signed a major contract with Expo 2030 Riyadh Company to serve as the lead design consultant for the detailed master plan and detailed design of public realm, landscape, infrastructure and utilities for Expo 2030 Riyadh and its legacy. This partnership represents a significant step toward delivering an event billed as “An Unprecedented World Expo”. Expo 2030 Riyadh is expected to feature nearly 197 participating countries and attract over 42 million visits to Pavilions covering approximately 6 million sqm. The event will offer a unique opportunity for participants to address shared challenges and showcase pioneering solutions for a sustainable future. Under the agreement, Buro Happold will provide comprehensive design and technical services, including, development of the detailed master plan, including a focus on event requirements and legacy phase elements, detailed design of the infrastructure works, uti
ThetaRay Report Warns Europe’s AML System at ‘Breaking Point’ as New Regulations Make AI Adoption Inevitable2.12.2025 11:00:00 CET | Press release
Study by EU regulatory expert Prof. Andrea Minto and ThetaRay VP Regulatory Affairs Yaron Hazan finds legacy AML tools unfit for Europe’s new regulatory era ThetaRay, a global leader in Cognitive AI financial crime compliance, today released a landmark study on the future of anti-money laundering in Europe. The study warns that Europe’s anti-money laundering (AML) system is approaching structural failure, and that financial institutions will be unable to meet upcoming supervisory expectations without advanced AI-driven monitoring and customer screening systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202058684/en/ Next Generation AML Solutions The report, “Next-Generation AML Solutions: An Analysis of AI-Based Tools vis-à-vis the Reform of the European AML Institutional and Substantive Architecture,” offers some of the most comprehensive examinations to date of how the EU’s sweeping AML reform package and the Artif
Siren Secures Investment to Advance AI-Driven Investigations for National Security2.12.2025 10:30:00 CET | Press release
Decade-Long Partnership Expands Unified Platform For Agencies To Combat Complex Threats Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The investment deepens a decade-long partnership between the two companies and accelerates development of Siren’s AI-driven platform, including Siren’s newly launched K9 AI Companion, used by national security, law enforcement, and financial crime agencies worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202354147/en/ Siren, the all-in-one investigation company, today announced a strategic investment from Elastic (NYSE: ESTC), the company behind Elasticsearch. The partnership combines the Elasticsearch Platform, which delivers real-time search, retrieval and anomaly detection across structured, unstructured, and streaming data, with Siren’s patented investigative intelligence technolo
P.I. Works Drives Stronger Network Results for Beeline Uzbekistan2.12.2025 10:00:00 CET | Press release
P.I. Works celebrates the success of its long-time client Beeline Uzbekistan, recognized by independent global analytics firms Opensignal and Ookla for excellence in mobile network performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202914682/en/ P.I. Works Drives Stronger Network Results for Beeline Uzbekistan Opensignal named Beeline Uzbekistan the country’s Fastest Mobile Internet provider and Most Consistent Mobile Network for the first half of 2025, while Ookla recognized the operator with the Best Mobile Video Experience award. These honors reflect the measurable impact of P.I. Works’ AI-driven automation, analytics, and optimization capabilities, combined with Beeline Uzbekistan’s strong commitments to investment and innovation. Partnership Powering Network Excellence A joint strategy to bring intelligence and efficiency into operations fuels this success. With automation, self-organizing capabilities, and
GMA with MOVIVA®: setting new standards in endoscopic bariatric treatment2.12.2025 09:59:00 CET | Press release
The innovative approach works from the inside of the stomach to help reduce hunger and to support weight loss Just a few months after the world’s first Gastric Mucosal Ablation (GMA) case using MOVIVA® at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA® is helping to establish a new era of endoscopic bariatric treatment – offering a less invasive option as obesity rates continue to rise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202355726/en/ GMA with MOVIVA® A promising alternative for bariatric patients: GMA with MOVIVA® GMA is an incisionless, minimally invasive endoscopic procedure. It targets the gastric fundus, the main site of ghrelin production – the so-called hunger hormone. By reducing ghrelin levels, patients experience less hunger. At the same ti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom